In this work, we report, for the first time, that GAS5 downregulation is not only associated with adenocarcinoma tumorigenesis and progression but is also associated with primary resistance to EGFR-TKIs, both in vitro and in vivo. Here, GAS5 is linked to adenocarcinoma.